CTCs are released from a primary or metastatic tumor and shed into the peripheral blood, where they can be isolated by size selection [262] or by targeting surface proteins such as EpCAM, MUC1, or HER2 [263]. Here, ERBB2 is linked to metastatic neoplasm.